Advanced Filters
noise

breast-cancer Clinical Trials

A listing of breast-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 2,264 clinical trials
P Pragya Yadav, Ph.D.

Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study

The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins. An …

19 - 90 years of age Female Phase N/A
Y Yan Xu, M.D.

ctDNA Monitoring in Early Breast Cancer

This is a observational, single center study, monitoring the circulating tumor DNA (ctDNA) in patients with early breast cancer and assessing the prognostic value and treatment outcome monitoring of ctDNA.

18 - 80 years of age All Phase N/A
k kerstin Faravel

Evaluation of the Efficacy of a Physical Therapy-yoga-patient Educational Program for Breast Cancer Patients With Pain Due to Hormonal Therapy Treatment.

As much as 50% of patients treated with hormonotherapy (HT) for breast cancer (BC) suffer from osteoarticular pain during treatment. Secondary effects have become a real issue because of their consequences on the patients' quality of life, but also on treatment efficacy and survival when they induce dose reduction or …

18 - 99 years of age Female Phase N/A
W Wenjin Yin

Disitamab Vedotin (RC48-ADC) in Breast Cancer

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.

years of age All Phase N/A
H Hannah Straughn

FES BPET-DBT in Newly Diagnosed Breast Cancer

Patients with newly diagnosed primary estrogen-receptor (ER) positive breast cancer, with at least one breast lesion that is 1.0 cm in diameter or greater, may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to 20 evaluable subjects …

18 years of age Female Phase 0
T Trial Manager

Safe De-escalation of Chemotherapy for Stage 1 Breast Cancer

The aim of this study is to assess the rates of circulating tumour DNA (ctDNA) in patients treated with surgery for stage 1 breast cancer that is HER2 positive or triple negative. The study will involve collecting blood samples from patients before and after surgery, if patients are enrolled after …

18 years of age All Phase N/A
R Rebekah Craver

Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA

The HARMONY trial is an interventional trial enrolling metastatic breast cancer (MBC). Current treatment of breast cancer uses clinical subtype information (e.g. hormone receptor-positive (HR+)) to help guide treatment options. Breast cancer can also be characterized by molecular subtype, but it is not known if this information is helpful in …

18 - 99 years of age All Phase N/A
G Gregory J Czarnota, PhD, MD

Use of Quantitative Ultrasound to Guide Adaptive Chemotherapy Among Women With Breast Cancer

The primary objective of this study is to assess the feasibility of randomizing breast cancer patients to quantitative ultrasound to guide adaptive Neoadjuvant Chemotherapy as compared to standard clinical monitoring and therapy. The Investigators have previously demonstrated that high-frequency ultrasound and spectroscopy, and recently conventional-frequency ultrasound and spectroscopy may be …

18 years of age Female Phase N/A
A Anna M Tanasijevic

Exercise in Metastatic Breast Cancer: EMBody

The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, supervised, progressive intensity aerobic and resistance training exercise for 16 weeks in this …

18 years of age All Phase N/A
P Pragya Yadav, Ph.D.

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.

18 - 90 years of age Female Phase 2

Simplify language using AI